Guggenheim Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $3.00

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price target reduced by equities research analysts at Guggenheim from $4.00 to $3.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price target indicates a potential upside of 411.42% from the company’s current price.

ADAP has been the topic of several other research reports. HC Wainwright decreased their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Thursday. StockNews.com downgraded shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Adaptimmune Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $3.16.

Adaptimmune Therapeutics Price Performance

Shares of NASDAQ:ADAP opened at $0.59 on Friday. The business has a fifty day moving average of $0.88 and a two-hundred day moving average of $1.03. The stock has a market cap of $150.02 million, a P/E ratio of -2.67 and a beta of 2.26. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 0.26. Adaptimmune Therapeutics has a 52-week low of $0.42 and a 52-week high of $2.05.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several large investors have recently modified their holdings of ADAP. Fullcircle Wealth LLC acquired a new position in shares of Adaptimmune Therapeutics during the third quarter worth about $33,000. Vontobel Holding Ltd. raised its stake in shares of Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after buying an additional 30,000 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Adaptimmune Therapeutics during the third quarter worth about $95,000. Boulder Hill Capital Management LP purchased a new position in shares of Adaptimmune Therapeutics during the 1st quarter worth approximately $143,000. Finally, Jane Street Group LLC increased its position in Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after buying an additional 98,581 shares in the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.